Frequent activation of mTOR signaling in trastuzumab-resistant NCI N87 (T-R) HER2 + gastric cancer cells identified by a parallel quantitative proteomics profiling suggested the need of an mTOR antagonist for the T-R HER + gastric cancers (Liu et al., 2017). Here, ERBB2 is linked to gastric cancer.